These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29062961)

  • 1. Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for
    Turner AEB; Gerson JE; So HY; Krasznai DJ; St Hilaire AJ; Gerson DF
    Synth Syst Biotechnol; 2017 Mar; 2(1):49-58. PubMed ID: 29062961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
    Skinner JM; Indrawati L; Cannon J; Blue J; Winters M; Macnair J; Pujar N; Manger W; Zhang Y; Antonello J; Shiver J; Caulfield M; Heinrichs JH
    Vaccine; 2011 Nov; 29(48):8870-6. PubMed ID: 21964055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine.
    Dinleyici EC; Yargic ZA
    Expert Rev Vaccines; 2009 Aug; 8(8):977-86. PubMed ID: 19627181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of pneumococcal disease prevention.
    Rodgers GL; Klugman KP
    Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23).
    Fairman J; Agarwal P; Barbanel S; Behrens C; Berges A; Burky J; Davey P; Fernsten P; Grainger C; Guo S; Iki S; Iverson M; Kane M; Kapoor N; Marcq O; Migone TS; Sauer P; Wassil J
    Vaccine; 2021 May; 39(23):3197-3206. PubMed ID: 33965258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants.
    Zangwill KM; Greenberg DP; Chiu CY; Mendelman P; Wong VK; Chang SJ; Partridge S; Ward JI
    Vaccine; 2003 May; 21(17-18):1894-900. PubMed ID: 12706674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children.
    Sigurdardottir ST; Center KJ; Davidsdottir K; Arason VA; Hjalmarsson B; Elisdottir R; Ingolfsdottir G; Northington R; Scott DA; Jonsdottir I
    Vaccine; 2014 Jan; 32(3):417-24. PubMed ID: 24300594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.
    Trück J; Jawad S; Goldblatt D; Roalfe L; Snape MD; Voysey M; Pollard AJ
    Pediatr Infect Dis J; 2016 Jul; 35(7):787-93. PubMed ID: 27088583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine.
    Gruber WC; Scott DA; Emini EA
    Ann N Y Acad Sci; 2012 Aug; 1263():15-26. PubMed ID: 22830997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
    Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
    Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current trends in development and manufacturing of higher-valent pneumococcal polysaccharide conjugate vaccine and its challenges.
    Jain SS; Singh VK; Kante RK; Jana SK; Patil RH
    Biologicals; 2024 Aug; 87():101784. PubMed ID: 39053122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides.
    Tan CY; Immermann FW; Sebastian S; Pride MW; Pavliakova D; Belanger KA; Watson W; Scott DA; Sidhu M; Jansen KU; Giardina PC
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30089644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of aluminum adjuvants on the stability of pneumococcal polysaccharide-protein conjugate vaccines.
    Smith WJ; Thompson R; Egan PM; Zhang Y; Indrawati L; Skinner JM; Blue JT; Winters MA
    Vaccine; 2023 Aug; 41(35):5113-5125. PubMed ID: 37321893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
    Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
    Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines.
    Chuck AW; Jacobs P; Tyrrell G; Kellner JD
    Vaccine; 2010 Jul; 28(33):5485-90. PubMed ID: 20554066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants.
    Puumalainen T; Zeta-Capeding MR; Käyhty H; Lucero MG; Auranen K; Leroy O; Nohynek H
    Pediatr Infect Dis J; 2002 Apr; 21(4):309-14. PubMed ID: 12075762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.